← Leaderboards
Kailash C Chadha
Kaps Biotech, Inc.
$862,499
Attributed
$1,724,998
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $502.6K · FY2018–22$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,724,998 · 1
By mechanism
R42$1,724,998 · 1
Top collaborators
- Willie Underwood4 shared
Others in their field
Other Emerging Leaders on “High Risk”
- Chanza Baytop · Westat, Inc.$271,217,917
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ted Ross · University Of Georgia$70,992,558
- Yunda Huang · Fred Hutchinson Cancer Center$69,424,989
- Bambra Strokes · Ppd Development Lp$65,000,267
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
High RiskAdoptionHealth Care CostsBiopsyBiotechnologyBenignBiological MarkersAftercareBurden Of IllnessCancer BiomarkersCancer DiagnosisCancer EtiologyCancer SurvivalCessation Of LifeClinical ApplicationCostCost EffectiveCytokineDecision MakingDiagnosisEarly Detection BiomarkersEarly DiagnosisFutureIl8 Gene
Grant awards (4)
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis$502,137
R42 · FY2022 · MD
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis$502,559
R42 · FY2021 · MD
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis$495,303
R42 · FY2020 · MD
KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis$224,999
R42 · FY2018 · MD